_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023-preview-1.jpg "PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023 from parp Video Screenshot Preview 1")
Gallery_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023-preview-3.jpg "PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023 from parp Video Screenshot Preview 3")
Gallery_parp-inhibitors-in-ovarian-cancer-clinical-updates-from-sgo-2023-preview-hqdefault.jpg "PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023 from parp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 59 minutes 14 seconds
👁 View: 1,000 times
Play Audio:👁 View: 1,000 times
Description:
Touch Medical Media Services
Touch Medical Media Services
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.webp "Linda Mileshkin, MBBS, of the Peter MacCallum Cancer Centre, discusses phase Ib trial findings on the anti–PD-1 monoclonal antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in advanced solid tumors.")
_an-overview-of-parp-inhibitors-in-ovarian-cancer.webp "Targeted Oncology")
_parp-inhibitors-for-ovarian-cancer.webp "VJOncology")
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.webp "Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer than previously recognized–– and clinical trials with PARP inhibitors.")
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.webp "James L. Gulley, MD, PhD, of the National Cancer Institute, discusses combined treatment approaches showing early evidence of clinical activity: agents such as vaccines or PARP inhibitors that can initiate an immune response, paired with agents such as checkpoint inhibitors that can facilitate the activity of tumor-directed immune cells.")
⏲ 2 min 33 sec ✓ 28-Jan-2018
_ctsc-124-stenoparib-and-covid-19.webp "Stenoparib Publication in MBio JournalnnStenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 and HCoV-NL63 human coronaviruses in vitro.nnMore info: https://joinpmi.com/ctsc-stenoparib-and-covid-19")
_parp-inhibitors-in-combination-with-nhas.webp "In this GU CONNECT programme from Dr Andrew Armstrong, you'll follow a patient through their prostate cancer journey and explore the clinical implementation of genetic testing and PARP inhibitors in combination with novel hormonal agents (NHAs). It follows Dr Neal Shore's animated video exploring PARPis as monotherapy.nnWatch the animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testi")
_what-key-factors-impact-prostate-cancer-treatment-decisions.webp "Prostate cancer expert Dr. Channing Paller reviews key variables that impact prostate cancer treatment decisions and explains immunotherapy, PARP inhibitors, and personalized medicine.nnDr. Channing Paller is Director of Prostate Cancer Clinical Research at Johns Hopkins Medicine. Learn more about Dr. Paller here: https://www.hopkinsmedicine.org/profiles/details/channing-paller")
_linda-mileshkin-mbbs-on-solid-tumors-early-treatment-study-results.jpg)
_an-overview-of-parp-inhibitors-in-ovarian-cancer.jpg)
_parp-inhibitors-for-ovarian-cancer.jpg)
_joshua-m-lang-md-on-prostate-cancer-best-of-the-journals.jpg)
_james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options.jpg)
_ctsc-124-stenoparib-and-covid-19.jpg)
_parp-inhibitors-in-combination-with-nhas.jpg)
_what-key-factors-impact-prostate-cancer-treatment-decisions.jpg)
![[+]](/images/menu.gif){kind=small}